Retatrutide's 26% weight loss is wild, but that new safety signal is the real story
Posted by weekendnate in Weight Loss & Metabolic - 1 points, 2 comments.
The BioSpace piece on the TRIUMPH-4 readout. 26% average weight loss at the higher doses, which honestly makes the tirzepatide numbers feel almost modest by comparison. The headline-grabber for me though was the safety signal they're flagging, because that's the part most people are gonna skim past and focus on the percent.
I've been tracking my own numbers on a GLP-1/GIP combo and the appetite suppression is unreal, but the cardiac and GI stuff is what I'd be watching like a hawk if I were considering stepping up to a triple agonist. Stronger isn't always better if the trade-off is a new side effect profile we don't fully understand yet.
For anyone actually running these in a clinical setting, are you seeing anything in vitals or bloodwork that would give you pause before jumping to a triple once it's available? Genuinely curious how people are weighing efficacy vs unknown long-term risk.
Comments
- talia45: Yeah tbh the TRIUMPH-4 numbers are eye-popping but the heart rate bump is the thing I keep coming back to. Doubling up GIP plus adding glucagon is a lot of pathways to push at once, and I get why regulators are gonna want longer cardio follow-up before this becomes a routine option. What jumps out to me, and I'd wanna know how others are thinking about this, is whether the cardiac signal is dose dependent or something we see across the board. If it's tied to the higher dose arm that might be mo
- weekendnate: Yeah the dose-dependency question is exactly where my head goes too. If the HR bump only shows up in the higher dose arm then it's a ceiling problem, not a class problem, and that's a much easier conversation with whoever's prescribing. On my dual agonist run my resting HR crept up maybe 4-5 bpm over the first couple months and then settled. Curious whether you'd see the same pattern with reta or if it's a straight linear climb. Did yours stay elevated or come back down once you held a steady d
Community discussion - research and educational context only. Not medical advice.